CoChat
Sign Up
Cited by 33

The DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.

In vitro validation of effects of BDNF-expressing mesenchymal stem cells on neurodegeneration in primary cultured neurons of APP/PS1 mice

Song, M.-S., Learman, C.R., Ahn, K.-C., Baker, G.B., Kippe, J., Field, E.M., Dunbar, G.L.·2015·Neuroscience
DOI 10.1016/j.neuroscience.2015.08.011
Open this paper in CoChat — free account

Abstract

Alzheimer's disease (AD), the most common type of dementia, is characterized by the presence of senile plaques, neurofibrillary tangles, and neuronal loss in defined regions of the brain including the hippocampus and cortex. Transplantation of bone marrow-derived mesenchymal stem cells (BM-MSCs) offers a safe and potentially effective tool for treating neurodegenerative disorders. However, the therapeutic effects of BM-MSCs on AD pathology remain unclear and their mechanisms at cellular and molecular levels still need to be addressed. In this study, we developed a unique neuronal culture made from 5xFAD mouse, an APP/PS1 transgenic mouse model (FAD neurons) to investigate progressive neurodegeneration associated with AD pathology and efficacy of brain-derived neurotrophic factor expressing-MSCs (BDNF-MSCs). Analyses of the expression of brain-derived neurotrophic factor (BDNF), synaptic markers and survival/apoptotic signals indicate that pathological features of cultured neurons made from these mice accurately mimic AD pathology, suggesting that our protocol provided a valid in vitro model of AD. We also demonstrated amelioration of AD pathology by MSCs in vitro when these FAD neurons were co-cultured with MSCs, a paradigm that mimics the in vivo environment of post-transplantation of MSCs into damaged regions of brains. To overcome failed delivery of BDNF to the brain and to enhance MSCs releasing BDNF effect, we created BDNF-MSCs and found that MSCs protection was enhanced…

Overview

Integrity signals

Registry

Crossref · 10.1016/j.neuroscience.2015.08.011

Cites

7 of 7 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Flagged first, then by citations

Research works printed but not linked: 56

  1. Altar, 1997, Anterograde transport of brain-derived neurotrophic factor and its role in the brain, Nature, 389, 856, 10.1038/39885 · DOI
  2. Bae, 2012, Bone marrow-derived mesenchymal stem cells contribute to the reduction of amyloid-beta deposits and the improvement of synaptic transmission in a mouse model of pre-dementia Alzheimer’s disease, Curr Alzheimer Res
  3. Blurton-Jones, 2006, Pathways by which Abeta facilitates tau pathology, Curr Alzheimer Res, 3, 437, 10.2174/156720506779025242 · DOI
  4. Bondolfi, 2002, Amyloid-associated neuron loss and gliogenesis in the neocortex of amyloid precursor protein transgenic mice, J Neurosci, 22, 515, 10.1523/JNEUROSCI.22-02-00515.2002 · DOI · Paper page
  5. Boxall, 2012, Markers for characterization of bone marrow mulitpotential stromal cells, Stem Cells Int, 2012, 975871, 10.1155/2012/975871 · DOI
  6. Brion, 2001, Neurofibrillary tangles and tau phosphorylation, Biochem Soc Symp, 81, 10.1042/bss0670081 · DOI
  7. Chen, 2002, Human bone marrow stromal cell cultures conditioned by traumatic brain tissue extracts: growth factor production, J Neurosci Res, 69, 687, 10.1002/jnr.10334 · DOI
  8. Coleman, 2004, A focus on the synapse for neuroprotection in Alzheimer disease and other dementias, Neurology, 63, 1155, 10.1212/01.WNL.0000140626.48118.0A · DOI · Paper page
  9. D’Amelio, 2010, Neuronal caspase-3 signaling: not only cell death, Cell Death Differ, 17, 1104, 10.1038/cdd.2009.180 · DOI
  10. De Miguel, 2010, Pluripotent stem cells: origin, maintenance and induction, Stem Cell Rev, 6, 633, 10.1007/s12015-010-9170-1 · DOI
  11. Ferrer, 1999, BDNF and full-length and truncated TrkB expression in Alzheimer disease. Implications in therapeutic strategies, J Neuropathol Exp Neurol, 58, 729, 10.1097/00005072-199907000-00007 · DOI
  12. Games, 1995, Alzheimer-type neuropathology in transgenic mice overexpressing V717F beta-amyloid precursor protein, Nature, 373, 523, 10.1038/373523a0 · DOI · Paper page
  13. George-Hyslop, 2001, Alzheimer’s disease. Unravelling the disease process, Lancet, 358, S1, 10.1016/S0140-6736(01)07014-3 · DOI
  14. German, 2003, Cholinergic neuropathology in a mouse model of Alzheimer’s disease, J Comp Neurol, 462, 371, 10.1002/cne.10737 · DOI
  15. Gordon, 2001, Correlation between cognitive deficits and Abeta deposits in transgenic APP+PS1 mice, Neurobiol Aging, 22, 377, 10.1016/S0197-4580(00)00249-9 · DOI
  16. Haass, 2007, Soluble protein oligomers in neurodegeneration: lessons from the Alzheimer’s amyloid beta-peptide, Nat Rev Mol Cell Biol, 8, 101, 10.1038/nrm2101 · DOI · Paper page
  17. Hardy, 1997, Amyloid, the presenilins and Alzheimer’s disease, Trends Neurosci, 20, 154, 10.1016/S0166-2236(96)01030-2 · DOI · Paper page
  18. Hock, 2000, Region-specific neurotrophin imbalances in Alzheimer disease: decreased levels of brain-derived neurotrophic factor and increased levels of nerve growth factor in hippocampus and cortical areas, Arch Neurol, 57, 846, 10.1001/archneur.57.6.846 · DOI · Paper page
  19. Holsinger, 2000, Quantitation of BDNF mRNA in human parietal cortex by competitive reverse transcription-polymerase chain reaction: decreased levels in Alzheimer’s disease, Brain Res Mol Brain Res, 76, 347, 10.1016/S0169-328X(00)00023-1 · DOI
  20. Hsiao, 1996, Correlative memory deficits, Abeta elevation, and amyloid plaques in transgenic mice, Science, 274, 99, 10.1126/science.274.5284.99 · DOI · Paper page
  21. Ittner, 2010, Dendritic function of tau mediates amyloid-beta toxicity in Alzheimer’s disease mouse models, Cell, 142, 387, 10.1016/j.cell.2010.06.036 · DOI · Paper page
  22. Jeronimo-Santos, 2014, Dysregulation of TrkB receptors and BDNF function by amyloid β peptide is mediated by calpain, Cereb Cortex
  23. Joyce, 2010, Mesenchymal stem cells for the treatment of neurodegenerative disease, Regen Med, 5, 933, 10.2217/rme.10.72 · DOI
  24. Kim, 2012, Soluble intracellular adhesion molecule-1 secreted by human umbilical cord blood-derived mesenchymal stem cell reduces amyloid-beta plaques, Cell Death Differ, 19, 680, 10.1038/cdd.2011.140 · DOI
  25. Kimura, 2009, Impairments in remote memory stabilization precede hippocampal synaptic and cognitive failures in 5xFAD Alzheimer mouse model, Neurobiol Dis, 33, 229, 10.1016/j.nbd.2008.10.006 · DOI · Paper page
  26. Laske, 2006, Decreased brain-derived neurotrophic factor (BDNF)- and beta-thromboglobulin (beta-TG)-blood levels in Alzheimer’s disease, Thromb Haemost, 96, 102, 10.1160/TH06-03-0173 · DOI
  27. Lee, 2010, Intracerebral transplantation of bone marrow-derived mesenchymal stem cells reduces amyloid-beta deposition and rescues memory deficits in Alzheimer’s disease mice by modulation of immune responses, Stem Cells, 28, 329, 10.1002/stem.277 · DOI
  28. Leyhe, 2009, Increase of BDNF serum concentration in lithium treated patients with early Alzheimer’s disease, J Alzheimers Dis, 16, 649, 10.3233/JAD-2009-1004 · DOI
  29. Li, 2009, Cerebrospinal fluid concentration of brain-derived neurotrophic factor and cognitive function in non-demented subjects, PLoS One, 4, e5424, 10.1371/journal.pone.0005424 · DOI
  30. Li, 2011, Soluble Abeta oligomers inhibit long-term potentiation through a mechanism involving excessive activation of extrasynaptic NR2B-containing NMDA receptors, J Neurosci, 31, 6627, 10.1523/JNEUROSCI.0203-11.2011 · DOI
  31. Longo, 2007, Small molecule neurotrophin receptor ligands: novel strategies for targeting Alzheimer’s disease mechanisms, Curr Alzheimer Res, 4, 503, 10.2174/156720507783018316 · DOI
  32. Lopez, 2003, Neuropathology of Alzheimer’s disease and mild cognitive impairment, Rev Neurol, 37, 155
  33. Mattson, 2003, Neuronal and glial calcium signaling in Alzheimer’s disease, Cell Calcium, 34, 385, 10.1016/S0143-4160(03)00128-3 · DOI
  34. Moloney, 2010, Potential of rat bone marrow-derived mesenchymal stem cells as vehicles for delivery of neurotrophins to the Parkinsonian rat brain, Brain Res, 1359, 33, 10.1016/j.brainres.2010.08.040 · DOI
  35. Mrak, 1996, Role of activated glia and of glial cytokines in Alzheimer’s disease: a review, EOS, 16, 80
  36. Murer, 2001, Brain-derived neurotrophic factor in the control human brain, and in Alzheimer’s disease and Parkinson’s disease, Prog Neurobiol, 63, 71, 10.1016/S0301-0082(00)00014-9 · DOI · Paper page
  37. Nagahara, 2009, Neuroprotective effects of brain-derived neurotrophic factor in rodent and primate models of Alzheimer’s disease, Nat Med, 15, 331, 10.1038/nm.1912 · DOI · Paper page
  38. Nagahara, 2013, Early BDNF treatment ameliorates cell loss in the entorhinal cortex of APP transgenic mice, J Neurosci, 33, 15596, 10.1523/JNEUROSCI.5195-12.2013 · DOI
  39. Ohtaki, 2008, Stem/progenitor cells from bone marrow decrease neuronal death in global ischemia by modulation of inflammatory/immune responses, PNAS, 105, 14638, 10.1073/pnas.0803670105 · DOI
  40. O’Leary, 2003, Design of potent peptide mimetics of brain-derived neurotrophic factor, J Biol Chem, 278, 25738, 10.1074/jbc.M303209200 · DOI
  41. Parr, 2007, Bone marrow-derived mesenchymal stromal cells for the repair of central nervous system injury, Bone Marrow Transplant, 40, 609, 10.1038/sj.bmt.1705757 · DOI
  42. Peng, 2005, Precursor form of brain-derived neurotrophic factor and mature brain-derived neurotrophic factor are decreased in the pre-clinical stages of Alzheimer’s disease, J Neurochem, 93, 1412, 10.1111/j.1471-4159.2005.03135.x · DOI · Paper page
  43. Salehi, 1996, Co-localization of high-affinity neurotrophin receptors in nucleus basalis of Meynert neurons and their differential reduction in Alzheimer’s disease, Neuroscience, 75, 373, 10.1016/0306-4522(96)00273-4 · DOI
  44. Sasaki, 2009, BDNF-hypersecreting human mesenchymal stem cells promote functional recovery, axonal sprouting, and protection of corticospinal neurons after spinal cord injury, J Neurosci, 29, 14932, 10.1523/JNEUROSCI.2769-09.2009 · DOI
  45. Scheff, 1993, Synapse loss in the temporal lobe in Alzheimer’s disease, Ann Neurol, 33, 190, 10.1002/ana.410330209 · DOI
  46. Scheff, 2007, Synaptic alterations in CA1 in mild Alzheimer disease and mild cognitive impairment, Neurology, 68, 1501, 10.1212/01.wnl.0000260698.46517.8f · DOI · Paper page
  47. Selkoe, 2003, Alzheimer’s disease: molecular understanding predicts amyloid-based therapeutics, Annu Rev Pharmacol Toxicol, 43, 545, 10.1146/annurev.pharmtox.43.100901.140248 · DOI
  48. Smith, 2006, Signaling mechanisms underlying Abeta toxicity: potential therapeutic targets for Alzheimer’s disease, CNS Neurol Disord: Drug Targets, 5, 355, 10.2174/187152706784111515 · DOI
  49. Song, 2008, Memantine protects rat cortical cultured neurons against beta-amyloid-induced toxicity by attenuating tau phosphorylation, Eur J Neurosci, 28, 1989, 10.1111/j.1460-9568.2008.06498.x · DOI
  50. Song, 2010, The antidepressant phenelzine protects neurons and astrocytes against formaldehyde-induced toxicity, J Neurochem, 114, 1405, 10.1111/j.1471-4159.2010.06857.x · DOI
  51. Tong, 2004, β-amyloid peptide at sublethal concentrations downregulates brain-derived neurotrophic factor functions in cultured cortical neurons, J Neurosci, 24, 6799, 10.1523/JNEUROSCI.5463-03.2004 · DOI · Paper page
  52. Walsh, 2002, Naturally secreted oligomers of amyloid beta protein potently inhibit hippocampal long-term potentiation in vivo, Nature, 416, 535, 10.1038/416535a · DOI · Paper page
  53. Wollen, 2010, Alzheimer’s disease: the pros and cons of pharmaceutical, nutritional, botanical, and stimulatory therapies, with a discussion of treatment strategies from the perspective of patients and practitioners, Altern Med Rev, 15, 223
  54. Zhang, 2014, Neural stem cell transplants improve cognitive function without altering amyloid pathology in an APP/PS1 double transgenic model of Alzheimer’s disease, Mol Neurobiol, 50, 423, 10.1007/s12035-014-8640-x · DOI
  55. Zhong, 1994, Expression of mRNAs encoding subunits of the N-methyl-D-aspartate receptor in cultured cortical neurons, Mol Pharmacol, 45, 846, 10.1016/S0026-895X(25)10198-3 · DOI
  56. Zilka, 2011, Mesenchymal stem cells rescue the Alzheimer’s disease cell model from cell death induced by misfolded truncated tau, Neuroscience, 193, 330, 10.1016/j.neuroscience.2011.06.088 · DOI

Cited by

Sorted by citations

Metadata

Authors
Song, M.-S., Learman, C. R., Ahn, K.-C., Baker, G. B., Kippe, J., Field, E. M., & Dunbar, G. L.
Venue
Neuroscience
Publisher
Elsevier BV
Published
2015-10
Volume
307
Pages
37-50
ISSN
0306-4522
DOI
10.1016/j.neuroscience.2015.08.011
Cited by
33
References
7
Language
en
Licence
www.elsevier.com/tdm/userlicense/1.0/ (tdm)
Funders
Field Neurosciences Institute

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review